# A Study Designed to Compare 2 Dose Strengths of TI Inhalation Powder in Adults With Type 1 Diabetes Mellitus and to Compare One of Those Formulations (30Units) With an Injection of Insulin Lispro

> **NCT00662857** · PHASE2 · COMPLETED · sponsor: **Mannkind Corporation** · enrollment: 29 (actual)

## Conditions studied

- Diabetes Mellitus: Type 1

## Interventions

- **DRUG:** Technosphere® Insulin Inhalation Powder
- **DRUG:** Technosphere Insulin® Inhalation Powder
- **DRUG:** RAA Population

## Key facts

- **NCT ID:** NCT00662857
- **Lead sponsor:** Mannkind Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2008-11
- **Final completion:** 2008-12
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2014-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00662857

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00662857, "A Study Designed to Compare 2 Dose Strengths of TI Inhalation Powder in Adults With Type 1 Diabetes Mellitus and to Compare One of Those Formulations (30Units) With an Injection of Insulin Lispro". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00662857. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*